LDS/Medical Tests/CALR (Calreticulin) Gene Mutation Analysis (exon 9 common variants)

CALR (Calreticulin) Gene Mutation Analysis (exon 9 common variants)

The CALR gene is located at 19p13.13 and codes for a chaperone protein, calreticulin. Calreticulin is a regulatory protein that resides primarily in the endoplasmic reticulum (ER) of cells but is also present in subtle amounts in the cytoplasm and on the cell surface. In ER, calreticulin ensures proper protein folding and localization. Additionally, the ER also serves as a store of calcium ions which are required for several cellular processes including growth, proliferation, and division. Calreticulin is also involved in the maintenance of optimal calcium ion concentration in the ER and thereby regulates gene activity, cellular growth, proliferation, and division. Calreticulin furthermore controls cellular adhesion and apoptosis. Mutations in the CALR gene result in defective calreticulin formation, and compromised protein production resulting in dysregulated cell development, growth, and proliferation. Mutations in the CALR gene are associated with myeloproliferative neoplasms, particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).

Approximately 70% of ET and PMF cases that do not have mutations in JAK2 or MPL harbor mutations in CALR. Essential thrombocythemia is characterized by prolonged platelet counts in excess of 450,000/uL and an increased risk of thrombosis, bleeding and a slight increase in leukemia risk. In primary myelofibrosis, the bone marrow is replaced by reticulin and eventually collagen fibrosis that eventually compromises the synthetic function of the marrow. Complications of PMF include pancytopenia, extramedullary hematopoiesis.

  • As an aid in the diagnosis of essential thrombocythemia
  • As an aid in the diagnosis of primary myelofibrosis
A positive result indicates the presence of a mutation in exon 9 of the CALR gene A negative result indicates the absence of a mutation in exon 9 of the CALR gene, however, doesn’t rule out the diagnosis of myeloproliferative neoplasms. Although, CALR mutation-mediated dysregulation is ruled out.

Negative for mutations analysis (no mutations or pathogenic variants detected)

Real-time- reverse transcription PCR, Capillary Electrophoresis, high-resolution melting (HRM) analysis and a Taqman® Real-Time PCR (RQ-PCR).

Whole blood, EDTA (Lavender-top), bone marrow (EDTA).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5 days
  • Frozen: Unacceptable
JAK2 gene mutation analysis, CBC with differential, PBS, bone marrow examination, BCR-ABL translocation, MPL proto-oncogene, comprehensive metabolic panel.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login